Company Overview and News
Pivotal Software Inc. PVTL, +1.29% jumped more than 8% in after-hours trading Tuesday after the company released its first quarterly earnings report since an April initial public offering. Shares in the software company, a joint venture from VMware Inc. VMW, -0.69% and EMC that is now majority owned by Dell Technologies Inc., hit price levels they have yet to see in regular trading. Pivotal reported a fiscal first-quarter net loss of $32.
DVMT PVTL VMW
Until early March, Advanced Micro Devices, Inc. (NASDAQ:AMD) stock was in a bearish phase. Part of this had to due with the market volatility as well as worries about competitive threats from mega rivals like NVIDIA Corporation (NASDAQ:NVDA) and Intel Corporation (NASDAQ:INTC).
DVMT TCEHY CSCO AMD MSFT TCTZF NVDA INTC BIDU HPE
Document Table of Contents
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.
IBM JD WDC APPN CG CRM HPE GS BABA DVMT ATHM TROW MSFT NTAP
When Maxine Waters, the Democratic representative from southern Los Angeles, toured Silicon Valley during the first week of May with fellow members of the Congressional Black Caucus, she was blunt about the technology industry’s lack of progress hiring black employees. Waters, standing at a lectern in front of a wall of windows at Lyft’s offices in San Francisco, said she was “floored” to learn that black workers make up 1 or 2 percent of the workforce at several prominent tech companies.
DVMT GOOGL GOOG
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB INTU DVMT GOOGL OCLCF MSFT GOOG DIS ORCL
Good morning and welcome to the SecureWorks First Quarter Fiscal 2019 Financial Results Conference Call. Following prepared remarks, we will conduct a question-and-answer session. [Operator Instructions] At this time, all participants are in a listen-only mode. We are webcasting this call live on the SecureWorks Investor Relations website. After the completion of the call, a recording of the call will be made available on the same site.
DVMT SCWX RHT
Advanced Micro Devices (NASDAQ:AMD) is currently trading for $14.60 per share, a level last seen in March 2017. Shares of AMD stock climbed steadily from early 2016 to early 2017 before hitting near that mark and beginning to zigzag mostly lower.
DVMT CSCO AMD MSFT BIDU
Good morning and welcome to the Fiscal Year 2019 First Quarter Earnings Conference Call for Dell Technologies, Inc. I’d like to inform all participants this call is being recorded at the request of Dell Technologies. This broadcast is the copyrighted property of Dell Technologies, Inc. Any rebroadcast of this information, in whole or part without the prior written permission of Dell Technologies is prohibited.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ VMW WFC.PRT WFC.PRR WFC.PRQ DVMT WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Dell Technologies Inc (NYSE:DVMT) stock was on a wild ride Monday after releasing its earnings report for the first quarter of 2018.
Han Solo stumbles, Roseanne Barr tweets, and Trump blusters: It was a bad week in the House That Walt Built. But investors should hold on.
C.WSA VICI GM.WS.A GM.WS.B GM.WS.C GE CHLKF WTFCW WTFC 0941 FISV WTFCM NAT DVMT CHL CGBBW GM.WSB WFCNP WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP MON C.PRU WFC.PRY GM WFC.PRX DAL WFC.PRW WFC.PRV C.PRS IBM WFC WFC.WS GEC C.PRL C C.PRJ C.PRK C.PRG WTFPP BMI C.PRC C.PRPCL GNE
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET